Management Considerations for Patients with Hidradenitis Suppurativa and Lupus Spectrum Disease: A Narrative Review. (PubMed, Dermatol Ther (Heidelb)) - Sep 30, 2026 - "Tumor necrosis factor (TNF)-α inhibitors (e.g., adalimumab, infliximab), which are mainstays of treatment for moderate-to-severe HS, can induce autoantibodies and trigger DILE. Other common medications used for HS, such as minocycline, have also been associated with reports of drug-induced lupus...Other treatment options, such as anifrolumab, interleukin (IL)-1 inhibitors, and JAK/tyrosine kinase (TYK)2 inhibitors are currently under investigation, with preliminary data supporting their role in managing both HS and lupus spectrum diseases. Herein, we propose a clinical decision framework to guide safe, individualized therapeutic strategies for clinicians treating this complex patient population."
Journal • Review • Cutaneous Lupus Erythematosus • Dermatology • Hidradenitis Suppurativa • Immunology • Inflammatory Arthritis • Lupus • Oncology • Systemic Lupus Erythematosus • TYK2
|
|
Ashley B Crew; Claire S Chung; Jennifer L Hsiao; Katrina H Lee; Kenan Kherallah; Stratos Christianakis
|